






# ENETS standardized (synoptic) reporting for neuroendocrine tumour pathology

Marie-Louise F. van Velthuisen<sup>1</sup>  | Anne Couvelard<sup>2</sup>  | Guido Rindi<sup>3,4,5</sup>  |  
Nicola Fazio<sup>6</sup>  | Dieter Hörsch<sup>7</sup> | Els J. Nieveen van Dijkum<sup>8</sup>  | Günter Klöppel<sup>9</sup>  |  
Aurel Perren<sup>10</sup> 

<sup>1</sup>Department Pathology, Erasmus MC, Rotterdam, The Netherlands

<sup>2</sup>Service de Pathologie, Hôpital Bichat AP-HP et Université de Paris, Paris, France

<sup>3</sup>Section of Anatomic Pathology, Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Roma, Italia

<sup>4</sup>Unit of Anatomic Pathology, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italia

<sup>5</sup>Roma European Neuroendocrine Tumor Society (ENETS) Center of Excellence, Roma, Italia

<sup>6</sup>Division of gastrointestinal medical oncology and neuroendocrine tumors, European Institute of Oncology (IEO), IRCCS, Milan, Italy

<sup>7</sup>CA Gastroenterologie, Zentralklinik Bad Berka GmbH, Bad Berka, Germany

<sup>8</sup>Department of Surgery, Cancer Centre Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

<sup>9</sup>Department of Pathology, Consultation Center for Pancreatic and Endocrine Tumors, TU Munich, Munich, Germany

<sup>10</sup>Institute of Pathology, University of Bern, Bern, Switzerland

## Correspondence

Marie-Louise F. van Velthuisen,  
Department Pathology, Erasmus MC,  
Rotterdam, The Netherlands.  
Email: m.vanvelthuisen@erasmusmc.nl

## Abstract

In recent years the WHO classification of neuroendocrine neoplasms (NEN) has evolved. Nomenclature as well as thresholds for grading have changed leading to potential confusion and lack of comparability of tumour reports. Therefore, the European Neuroendocrine Tumour Society (ENETS) has set-up an interdisciplinary working group to develop templates for a pathology data set for standardised reporting of NEN. Experts of various disciplines, members of the ENETS Advisory Board, formed a taskforce that discussed and decided on the structure, content and the number of templates needed for reporting the most common NEN. The selection of the required items was based on the WHO classification of digestive system tumours, the WHO classification of tumours of the lung and mediastinum and on “ENETS standard of care” reports. The final proposal of the working group was approved by the ENETS Advisory Board. Templates for synoptic reporting were created for the seven most common NEN primary sites, that is, stomach, duodenum, jejunum-ileum, appendix, colon-rectum, pancreas, lung and mediastinum. In addition, a general template for reporting biopsies was designed. The templates allow the recording of the essential items on differentiation, proliferation (Ki-67 and mitosis), neuroendocrine features (positivity for chromogranin A and synaptophysin) and stage as well as several optional markers especially helpful for the distinction of neuroendocrine tumours (NET) from neuroendocrine carcinomas (NEC). In summary, this paper presents the content and development of synoptic reports for most sites of NEN by a multidisciplinary team of international experts in the field, which could help to improve unambiguous reporting of NEN.

## KEYWORDS

NEC, NET, neuro endocrine neoplasm, pathology report, synoptic report

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2022 The Authors. *Journal of Neuroendocrinology* published by John Wiley & Sons Ltd on behalf of British Society for Neuroendocrinology.

## 1 | INTRODUCTION

Pathological reports are the basis of diagnosis and treatment in the vast majority of malignancies including neuroendocrine neoplasms (NEN). The information conveyed in these reports changes over time depending on the reigning WHO classification. Traditionally, pathology reports are generated in a free text format. These reports vary from institution to institution and even between pathologists of an individual institution. There is therefore a need for standardised reporting.

The function of pathologists is to collect, process, synthesize and communicate morphological information that guides diagnosis and treatment of NEN. Important quality criteria for this process are accuracy, completeness, adherence to current guidelines and speed. The introduction of synoptic reporting (or structured reporting) has proven in multiple studies and tumour types to improve completeness and adherence to guidelines,<sup>1</sup> with slightly increased workload well tolerated by pathologists due to increased quality.

Synoptic (from Greek, synopsis; overview) reports have been introduced by national pathology societies over the last years including Australian (RCPA), British (RCPATH) and American (CAP) societies. Synoptic reports (or structured reports) define both the minimal content (required data elements, RDE) as well as the structure and terminology.<sup>2</sup> Each required data element is named, followed by the "content", leading to a paired format. The College of American Pathologists (CAP) has been instrumental for implementation of synoptic reports and declared the use of these reports mandatory for CAP-accreditation.

Over the last years, the International Collaboration for Cancer Reporting (ICCR) has been founded, sponsored by increasing numbers of national pathology societies. The ICCR aims to define internationally accepted synoptic reports of the main cancer types, with a well-defined process to ensure broad consensus, reflection of the best evidence available and adaptation to novel WHO classifications.<sup>3</sup> In subsequent years, ICCR will provide reports on various tumour types in an increasing number of languages (in 2021 English, Spanish, Portuguese, and French). Templates for reports on NEN from different organs will follow, when templates for the more frequent tumour types have been implemented.

As an interdisciplinary society, ENETS has contributed significantly to development of the classification, and grading of NEN as well as to the definition of content of pathology reports for NEN by issuing consensus- and standard of care guidelines.<sup>4-7</sup> To bridge the timespan until publication of ICCR-guidelines for well differentiated NEN (neuroendocrine tumours [NET]), ENETS decided to set up pathology reporting guidelines for NET (well differentiated neuroendocrine tumours) as well as NEC (neuroendocrine carcinomas). Application of ICCR-guidelines of carcinomas of the gastrointestinal tract for NEC is a valid alternative; however, these guidelines cannot be used for NET.

## 2 | METHOD

An international working group of the ENETS advisory board was initiated in 2018. In a workshop during the ENETS Advisory Board Meeting in Mallorca, the working group decided to develop synoptic/structured reports for the most frequent gastro-enteropancreatic NEN and thoracic NEN, applicable to resection as well as biopsy specimens.

To define required data elements, the respective WHO classifications<sup>8,9</sup> as well as the requirements defined in the "ENETS standards of care in pathology"<sup>4</sup> were used. Only findings based on widely available methods were defined as mandatory, more novel techniques and the use of novel biomarkers were defined as optional. A structure and first draft of the report for pancreatic NET (PanNET) was elaborated in the working group and approved by the interdisciplinary ENETS Advisory Board Meeting in Mallorca.

Consensus was reached for the structure of the ENETS synoptic reports as well as for the following reports to be developed: Gastric NEN, duodenal NEN, jejuno-ileal NEN, appendiceal NEN, colorectal NEN, pancreatic NEN and thoracic NEN, as well as for a generic report for small biopsies independent from their anatomical site.

For reasons of usability, it was decided to use Microsoft Word templates with dropdown options to generate the reports.

In several iterations the working group has developed these reports and the results were presented to the entire Advisory Board during the 2019 meeting in Vienna. After approval by the Advisory Board, the reports have been made available to all ENETS Centres of Excellence (CoE) for consultation until June 2020, and minor adaptations have been implemented by the working group based on suggestions from this consultation. Final changes have been made by the working group to standardise nomenclature among all documents in 2021.

Updates of the synoptic report templates are planned and will be initiated by the ENETS Executive Committee, if required by changes of the WHO or TNM classifications.

## 3 | RESULTS

Eight templates for standardised reports were constructed. One general template for biopsies and seven site-specific templates for resection specimens. All templates had the same basic structure starting with a summary including the diagnosis, followed by headings on tumour type, biomarkers, and optional markers, permitting the classification of the NEN. For site-specific templates for resections the pTNM classification was added to the summary, followed by a heading on clinics and macroscopy. Items for local tumour extension were added to the heading of the items needed to classify the tumour type and a heading for vascular invasion, perineural invasion and lymph node status was included in these templates. Furthermore, specific items were added to the site-specific templates.

In all templates, items on differentiation, necrosis, mitotic count, Ki-67 index and positivity for chromogranin A and synaptophysin were incorporated as a minimal data set, with keratin, SSTR2, P53, RB and hormone expressions as optional markers.

Site specific items were:

1. Different tumour nomenclature in thoracic-NEN
2. The type of NEN for gastric NET (type 1 in the background of atrophic gastritis, type 2 for NET due to other causes of hypergastrinaemia and type 3 for NET without hypergastrinaemia).
3. DAXX and ATRX staining for pancreatic NET
4. Size of the biggest lymph node metastasis in small intestinal NET
5. Depth of extension into the mesoappendix for appendiceal NET

The immunohistochemical results for biomarkers, if present, are reported as percentage of positive tumour cells except for reporting of p53, RB and SSTR2 where the options in the dropdown menus guide the interpretation of the staining pattern. For example, for P53 staining mutational pattern is to be discriminated from wild-type pattern, 0% or more than 90% staining of tumour cells both suggesting the presence of a p53 mutation, while all other staining patterns are compatible with wild-type p53.<sup>10</sup>

The templates are available on the ENETS website ([www.enets.org](http://www.enets.org)) for all ENETS members.

## 4 | DISCUSSION

NEN are most frequently found in the lung, mediastinum, gastrointestinal tract, and pancreas. Although many organs are affected, NEN are rare tumours, and also show site specific characteristics. Nomenclature of NEN has been evolving in the last decades, in some instances adding to the confusion of interpretation of pathology reports. However, it has become clear that a limited set of parameters defines clinically relevant patient groups. In 2004 the WHO classification of thoracic NEN, based on mitotic count, was introduced and has not been changed since then.<sup>11</sup> In 2010, the WHO classification of gastrointestinal and pancreatic NEN introduced the concept of well and poorly differentiated NEN, that is, NET and NEC, respectively, and also graded these NEN on the basis of the Ki-67 index in NET G1 and G2 and NEC G3.<sup>11</sup> The revised WHO classifications in 2017<sup>9</sup> and 2019<sup>8</sup> introduced the concept of NET G3 in the pancreas and gastrointestinal tract and exempted the NEC from any grading. These classifications use different nomenclature and different thresholds for separating patient groups, but similar features and biomarkers are used. In a recent publication Zandee et al.<sup>12</sup> showed that if these parameters were present in the report the tumours could be classified according to recent standards irrespective of the nomenclature used in the pathology report, or the reigning WHO classification at the time the report was made, thus demonstrating the relevance of a minimal dataset for these tumours.

The developed templates contain the elements stated in the ENETS pathology consensus guidelines for the standards of care.<sup>4</sup> The biomarkers define the neuroendocrine nature of the tumour (chromogranin A and synaptophysin), the differentiation of the tumour (well differentiated vs. poorly differentiated) and the proliferative activity (Ki-67 index, mitotic count, and necrosis). Since various grading thresholds for proliferative indices exist in the different WHO-classifications, the templates ask for the raw numbers so that the reports remain usable if threshold values should change in future classifications. For similar reasons, the other biomarkers are scored in percentage of positive cells. This could prove important for the classification of mixed tumours (MiNEN) in the future. There has been some debate for using the H-index for scoring these immunohistochemical staining results,<sup>13</sup> but this proved to be too cumbersome in daily practice to be incorporated in the templates. A similar strategy is used for the building blocks of TNM classification, for example, numbers of lymph nodes examined and numbers of lymph nodes with metastasis are both registered. Preserving the capacity to generate not only N-stage according to TNM but also lymph node ratio, or minimal numbers of lymph nodes examined at each site.

In view of future developments, some optional biomarkers are included in the templates that at the time of development were not part of the standards of care. P53 and RB are thus incorporated as optional biomarkers as they emerge as helpful in the differential diagnosis of NET G3 versus NEC. The immunohistochemical staining patterns for these proteins reflect the underlying molecular changes that seem to be important in the clinical behaviour as NEC and also predicting therapy response as is suggested for tumours with RB mutations as often seen in small cell carcinoma.<sup>14 15</sup>

The template for pancreatic NEN also allows, in addition to the above-mentioned biomarkers, to record the staining patterns for DAXX and ATRX as the staining pattern of these two proteins reflects the mutational status of the underlying genes. A mutation in one of these genes is associated with an adverse outcome<sup>16</sup> and can be found in NET G3 but excludes NEC.<sup>17</sup> The dropdown menus for reporting the biomarkers reflecting the mutational status of the genes described guide the user to report the results in this light.

Clinical data are limited to an absolute minimum in the templates, encompassing only the site of origin of the biopsy or the resection. Impending challenges are to see if and how these templates will be implemented in daily practice in different centres and countries, to measure their effect and see if they are indeed an important improvement.

## 5 | CONCLUSION

As NEN are rare lesions occurring in many sites and as nomenclature and classification of NEN are rapidly evolving, it is especially important that essential pathological parameters are communicated unambiguously. This publication provides synoptic reports for NEN of the most common localisations, and thus meets an urgent need for standardised NEN reporting.

## CONFLICT OF INTERESTS

Marie-Louise van Velthuisen, Anne Couvelard, Els J. Nieveen van Dijkum, Günter Klöppel and Aurel Perren have no conflicts of interest. Guido Rindi has received speakers fees from AAA and is consultant for Bracco. Nicola Fazio has received speakers fees from AAA, Hutchinson MediPharma, Merck and Novartis. Dieter Hörsch has received personal fees and grants from Lexicon Pharmaceuticals, Inc., Ipsen Pharmaceuticals, Inc., Novartis Pharmaceuticals, Inc., and Pfizer Pharmaceuticals, Inc., and advisory board honoraria from Advanz Pharma USA.

## AUTHOR CONTRIBUTIONS

**Marie-Louise van Velthuisen:** Conceptualization; Data curation; Methodology; Project administration; Writing – original draft; Writing – review & editing. **Anne Couvelard:** Conceptualization; Writing – review & editing. **Guido Rindi:** Conceptualization; Writing – review & editing. **Nicola Fazio:** Conceptualization; Writing – review & editing. **Dieter Hoersch:** Writing – review & editing. **Els Nieveen van Dijkum:** Conceptualization; Writing – review & editing. **G. Kloepfel:** Conceptualization; Writing – review & editing. **Aurel Perren:** Conceptualization; Formal analysis; Methodology; Writing – original draft; Writing – review & editing.

## PEER REVIEW

The peer review history for this article is available at <https://publons.com/publon/10.1111/jne.13100>.

## DATA AVAILABILITY

The proposed templates of synoptic reports for pathology will be publically available on the ENETS website: [www.enets.org](http://www.enets.org).

## ORCID

Marie-Louise F. van Velthuisen  <https://orcid.org/0000-0003-0435-9494>

Anne Couvelard  <https://orcid.org/0000-0002-6316-1210>

Guido Rindi  <https://orcid.org/0000-0003-2996-4404>

Nicola Fazio  <https://orcid.org/0000-0001-6869-0704>

Els J. Nieveen van Dijkum  <https://orcid.org/0000-0002-3029-6071>

Günter Klöppel  <https://orcid.org/0000-0002-6688-086X>

Aurel Perren  <https://orcid.org/0000-0002-6819-6092>

## REFERENCES

- Sluijter CE, van Lonkhuijzen LRCW, van Slooten HJ, Nagtegaal ID, Overbeek LH. The effects of implementing synoptic pathology reporting in cancer diagnosis: a systematic review. *Virchows Arch*. 2016;468(6):639-649.
- Leslie KO, Rosai J. Standardization of the surgical pathology report: formats, templates, and synoptic reports. *Semin Diagn Pathol*. 1994;11(4):253-257.
- Ellis D, Srigley J. Does standardised structured reporting contribute to quality in diagnostic pathology? The importance of evidence-based datasets. *Virchows Arch*. 2016;468(1):51-59.
- Perren A, Couvelard A, Scazecz JY, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pathology: diagnosis and prognostic stratification. *Neuroendocrinology*. 2017;105(3):196-200.
- Rindi G, Klöppel G, Alhman H, et al. TNM staging of foregut (neuro) endocrine tumors: a consensus proposal including a grading system. *Virchows Arch*. 2006;449(4):395-401.
- Rindi G, Klöppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. *Virchows Arch*. 2007;451(4):757-762.
- Salazar R, Wiedenmann B, Rindi G, Ruzsiewicz P. ENETS 2011 consensus guidelines for the management of patients with digestive neuroendocrine tumors: an update. *Neuroendocrinology*. 2012;95(2):71-73.
- Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. *Histopathology*. 2020;76(2):182-188.
- Lloyd RV, Osamura RY, Kloepfel G, Rosai G. WHO Classification of Tumours of Endocrine Organs. WHO/IARC Classification of Tumours; 4th Edition. Vol. 10. 2017. IARC.
- Köbel M, Piskorz AM, Lee S, et al. Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. *J Pathol Clin Res*. 2016;2(4):247-258.
- Editorial Board. WHO Classification of Tumours: Thoracic Tumors. WHO Classification of Tumours; 5th Edition. Vol. 5. 2021. IARC.
- Zandee WT, van der Zwan JM, de Herder WW, van Velthuisen MLF. Importance of complete pathology reporting for neuroendocrine carcinoma: WHO guidelines are a good start but not enough. *Neuroendocrinology*. 2020;110(11-12):994-1000.
- Cros J, Hentic O, Rebours V, et al. MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors. *Endocr Relat Cancer*. 2016;23(8):625-633.
- Derks JL, Rijnsburger N, Hermans BCM, et al. Clinical-pathological challenges in the classification of pulmonary neuroendocrine neoplasms and targets on the horizon for future clinical practice. *J Thorac Oncol*. 2021, 16(10):1632-1646.
- Oka N, Kasajima A, Konukiewitz B, et al. Classification and prognostic stratification of bronchopulmonary neuroendocrine neoplasms. *Neuroendocrinology*. 2020;110(5):393-403.
- Marinoni I, Kurrer AS, Vassella E, et al. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. *Gastroenterology*. 2014;146(2):453-460.
- Tang LH, Basturk O, Sue JJ, Klimstra DS. A practical approach to the classification of WHO grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas. *Am J Surg Pathol*. 2016;40(9):1192-1202.

**How to cite this article:** van Velthuisen M-LF, Couvelard A, Rindi G, et al. ENETS standardized (synoptic) reporting for neuroendocrine tumour pathology. *J Neuroendocrinol*. 2022;00:e13100. doi:[10.1111/jne.13100](https://doi.org/10.1111/jne.13100)

## APPENDIX

## ENETS ADVISORY BOARD MEETING PARTICIPANTS IN 2018

Arnold, R. (Zentrum für Innere Medizin, Universitätsklinikum Marburg, Marburg, Germany); Bartsch, D. K. (Department of Visceral-, Thoracic- and Vascular Surgery at the Philipps-University Marburg, Marburg, Germany); Belli, S.H. (Instituto Alexander Fleming, Buenos Aires, Argentina); Borbath, I. (Department of Hepato-Gastroenterology, Cliniques universitaires saint-Luc, Bruxelles, Belgium); Caplin, M. (Neuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free Hospital and University College London, London, United Kingdom); Castaño, J.P. (Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain); Chen, J. (Center for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center / Department of Oncology, Shanghai Medical College, Fudan University / Pancreatic Cancer Institute, Fudan University / Shanghai Pancreatic Cancer Institute, Shanghai, China); Costa, F.P. (Centro de Oncologia of Hospital Sírio Libanês, Sao Paulo, Brazil); de Herder W.W. (Department of Internal Medicine, Section of Endocrinology, Erasmus MC, Rotterdam, the Netherlands); Deroose, C.M. (University Hospitals Leuven, Nuclear Medicine and KU Leuven, Department of Imaging and Pathology, Nuclear Medicine & Molecular Imaging, Leuven, Belgium); Dromain, C. (Department of Radiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland); Faggiano, A. (Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy); Falconi, M. (Department of Surgery, Università Vita-Salute, San Raffaele Hospital IRCCS, Milan, Italy); Falkerby, J. (Department of oncology and endocrine tumors, Uppsala University Hospital, Uppsala, Sweden); Frilling, A. (Imperial College London, Department of Surgery and Cancer, Hammersmith Hospital, London, United Kingdom); Garcia-Carbonero, R. (Department of Oncology, Hospital Universitario Doce de Octubre, Ima12, UCM, Madrid, Spain); Grande, E. (Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain); Grozinsky-Glasberg, S. (Neuroendocrine Tumor Unit, Endocrinology & Metabolism Department, Division of Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel); Hand, P. (London North West University Healthcare Trust, London, United Kingdom); Hicks, R.J. (Neuroendocrine Service, the Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia); Howe, J.R. (Department of Surgery, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA); Jensen, R.T. (Gastrointestinal Cell Biology Section, Digestive Disease Branch, National Institute of Health, Bethesda, USA); Kolarova, T. (International Neuroendocrine Cancer Alliance, Sofia, Bulgaria); Kos-Kudła, B. (Department of Endocrinology and Neuroendocrine Tumors, Medical University of Silesia, Katowice, Poland); Koumariou A. (National and Kapodistrian University of Athens, Hematology Oncology Unit, 4th Department of Internal Medicine, Athens, Greece); Krejs, G.J. (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria); Krenning, E.P. (Erasmus MC, Cyclotron Rotterdam BV, Rotterdam, the Netherlands); Krishna, B.A. (Nuclear Medicine department, Lilavati Hospital and Research Centre, Mumbai, India); Leyden, S. (Neuroendocrine Cancer Australia, Blairgowrie, Australia); Masui, T. (Kyoto University, Kyoto, Japan); Niederle, B. (Department of Surgery, Medical University of Vienna, Vienna, Austria); Öberg, K. (Department of Endocrine Oncology, University Hospital Uppsala, Uppsala, Sweden); O'Toole, D. (National Centre for Neuroendocrine Tumours, St. James's and St. Vincent's University Hospitals & Trinity College Dublin, Dublin, Republic of Ireland); Pape, U.-F. (Department of Internal Medicine and Gastroenterology, Asklepios Klinik St. Georg, Asklepios Tumorzentrum Hamburg, Hamburg, Germany); Pavel, M. (Department of Medicine 1, Universitätsklinikum Erlangen, Erlangen, Germany); Prasad, V. (Department of Nuclear Medicine, University Ulm, Ulm, Germany); Ramage, J.K. (Kings Health Partners NET Centre, Institute of Liver Studies, King's College Hospital NHS Foundation Trust, London, United Kingdom / Hampshire Hospitals NHS foundation trust, Hampshire, United Kingdom); Reed, N.S. (Beatson Oncology Centre (BOC), Glasgow, United Kingdom); Rinke, A. (Philipps University Marburg and University Hospital Gießen and Marburg (UKGM), Division of Gastroenterology and Endocrinology, Marburg, Germany); Rothmund, M. (Philipps-Universität Marburg, Marburg, Germany); Ruszniewski, P. (Department of Gastroenterology-Pancreatology, Beaujon Hospital and Université de Paris, Clichy, France); Singh, S. (Sunnybrook Health Sciences Centre and University of Toronto, Toronto, Canada); Sundin, A. (Department of Surgical Sciences, Uppsala University, Radiology & Molecular Imaging, Uppsala University Hospital, Uppsala, Sweden); Toumpanakis, C. (Neuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free Hospital and University College London, London, United Kingdom); Valle, J.W. (Department of Medical Oncology, University of Manchester/The Christie NHS Foundation Trust, Manchester, United Kingdom); Verslype, C. (University Hospitals Leuven and KU Leuven, Leuven, Belgium); Vullierme, M.P. (Department of Radiology, Hôpital Beaujon - Hôpitaux Universitaires Paris Nord Val de Seine, Paris Diderot-Paris 7 University / Université de Paris, Paris, France); Welin, S. (Endocrine Oncology, Uppsala University Hospital, Uppsala, Sweden); Wiedenmann, B. (Charité Universitätsmedizin Berlin, Berlin, Germany); Zhao, H. (CNETS, Beijing, China).